Introduction
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Present key elements of study design early in the paper Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Participants 6 (a) Cohort study-Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
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Cross-sectional study-Give the eligibility criteria, and the sources and methods of selection of participants (b) Cohort study-For matched studies, give matching criteria and number of exposed and unexposed 
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Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file. ART = antiretroviral therapy; VCT = voluntary counseling and testing † probabilities modeled using segmented linear regression models: predicted probability = Baseline + b1*Pre-Treat All Trend + b2 * Treat All Change + b3 * Treat All Trend ‡ Refers to the predicted probability of outcome at the beginning of the study period, b0 § Refers to the modeled change in predicted probability of outcome per month during the pre-Treat All period, b1 ¶ Refers to the modeled change in predicted probability of outcome immediately after implementation of Treat All compared to immediately before implementation, b2 # Refers to the modeled difference in trend in predicted probability relative to the pre-Treat All period, b3
5-7, Tab
Supplemental n/a n/a n/a n/a CD4 cell count <200 versus ³500 cells/mm3 0. n/a n/a n/a n/a ART initiation <30 days (versus not initiated in <30 days) - ART = antiretroviral therapy; RR = rate ratio; CI = confidence interval; VCT = voluntary counseling and testing; BMI = body mass index; WHO = World Health Organization † Other includes tuberculosis program, referral from primary care, referral from inpatient hospitalization, sex worker outreach, mobile VCT *P <0.05; **P <0.01
